MODTX Stock Overview
A biotechnology company, develops a treatment for sepsis and septic shock in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Modus Therapeutics Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.76 |
| 52 Week High | SEK 2.89 |
| 52 Week Low | SEK 0.88 |
| Beta | 0.63 |
| 1 Month Change | 37.50% |
| 3 Month Change | 29.41% |
| 1 Year Change | -4.86% |
| 3 Year Change | -50.63% |
| 5 Year Change | n/a |
| Change since IPO | -66.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| MODTX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.4% | 3.4% | 1.9% |
| 1Y | -4.9% | 16.9% | 7.6% |
Return vs Industry: MODTX underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: MODTX underperformed the Swedish Market which returned 6.3% over the past year.
Price Volatility
| MODTX volatility | |
|---|---|
| MODTX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: MODTX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MODTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2 | John Öhd | www.modustx.com |
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB (publ) Fundamentals Summary
| MODTX fundamental statistics | |
|---|---|
| Market cap | SEK 63.25m |
| Earnings (TTM) | -SEK 14.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs MODTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MODTX income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 14.90m |
| Earnings | -SEK 14.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MODTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:29 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Modus Therapeutics Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ludvig Svensson | Penser Access |
| Maria Karlsson Osipova | Penser Access |